⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations

Vivek Subbiah Vaibhav Sahai Dejan Maglic Kamil Bruderek B. Barry Touré Songping Zhao Roberto Valverde Patrick J. O’Hearn Demetri T. Moustakas Heike Schönherr Nastaran Gerami-Moayed Alexander M. Taylor Brandi M. Hudson Damian J. Houde Debjani Pal Lindsey Foster Hakan Günaydin Pelin Ayaz Dina A. Sharon Lipika Goyal Alison M. Schram Suneel Kamath Cori Ann Sherwin Oleg Schmidt‐Kittler Kai Yu Jen Fabien Ricard Beni B. Wolf David E. Shaw Donald A. Bergstrom James Watters Jessica B. Casaletto

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplementary Figure 1. RLY-4008 is an irreversible inhibitor of FGFR2.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Subbiah et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522eb1 https://doi.org/10.1158/2159-8290.27025772.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
2Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
3Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
4Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
5Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024

Data from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024
Supplementary Video S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations2024